Plant Name: Datura stramonium
Taxonomic Information:
Plant ID: NPO6495
Plant Latin Name: Datura stramonium
Taxonomy Genus: Datura
Taxonomy Family: Solanaceae
Plant External Links:
NCBI TaxonomyDB:
4076
Plant-of-the-World-Online:
314738-2
Used in Medicines:
Country/Region:
China; Indonesia; IndiaTraditional Medicine System:
Indian Folk; Unani; Siddha; Ayurveda; TCM; HomeopathyMedicinal Functions:
Anodyne; Anthelmintic; Antiasthmatic; Antidandruff; Antiinflammatory; Antispasmodic; Hallucinogenic; Hypnotic; Mydriatic; Narcotic
Geographical Distribution:
Turkmenistan; Ethiopia; Swaziland; Argentina; Bolivia; Cameroon; Ghana; Saudi Arabia; Cape Verde; Spain; Netherlands; Jamaica; Tanzania; New Zealand; Yemen; Pakistan; Albania; India; Lesotho; Kenya; Tajikistan; Turkey; Afghanistan; Bangladesh; Eritrea; France; Rwanda; Somalia; Peru; Laos; Norway; Cote d'Ivoire; Benin; Cuba; Togo; China; Dominican Republic; Ukraine; Libya; Indonesia; Mauritius; Sweden; Belarus; Mali; Russia; Bulgaria; United States; Romania; Angola; Portugal; South Africa; Cyprus; Austria; Mozambique; Uganda; Hungary; Niger; Brazil; Guinea; Costa Rica; Bahamas; Nigeria; Ecuador; Australia; Iran; Algeria; Chile; Belgium; Haiti; Belize; Gambia; Poland; Morocco; Namibia; Switzerland; Iraq; Chad; Mexico; Uzbekistan; Tunisia; Colombia; Burundi; Taiwan; Fiji; Madagascar; Italy; Sudan; Nepal; Venezuela; Zambia; Malawi; Zimbabwe; Germany; Denmark; Kazakhstan; Mauritania; Trinidad and Tobago; Honduras; Myanmar; Equatorial Guinea; Egypt; United Kingdom; Congo; Greece; Sri Lanka; Botswana
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA1D; CHRM2; CHRM3; CHRM4; CHRM5; CHRM1; HTR2C; | |
| BLM; HPGD; GFER; HSD17B10; ALDH1A1; POLB; | |
| CA2; CA12; CA9; CA7; | |
| CASP1; CASP7; | |
| NFKB1; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP1A2; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Small molecule receptor (family A GPCR) | ADRA1D | Alpha-1d adrenergic receptor | P25100 | CHEMBL223 |
| Small molecule receptor (family A GPCR) | CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 | CHEMBL211 |
| Small molecule receptor (family A GPCR) | CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 | CHEMBL245 |
| Small molecule receptor (family A GPCR) | CHRM4 | Muscarinic acetylcholine receptor M4 | P08173 | CHEMBL1821 |
| Small molecule receptor (family A GPCR) | CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 | CHEMBL2035 |
| Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0023052; signaling | GO:0007271; synaptic transmission, cholinergic | 9.340E-11 | 1.849E-07 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.708E-09 | 3.099E-06 | CA12, CA2, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.256E-08 | 8.777E-05 | CA12, CA2, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.662E-07 | 1.905E-04 | CA12, CA2, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 7.753E-07 | 6.835E-04 | BLM, CA2, CA9, CASP1, CASP7, CYP1A2, HPGD, NFKB1 |
| CC | GO:0044456; synapse part | GO:0045211; postsynaptic membrane | 3.358E-06 | 2.521E-03 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.712E-06 | 2.608E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0004435; phosphatidylinositol phospholipase C activity | 3.685E-06 | 2.608E-03 | CHRM1, CHRM3, CHRM5 |
| BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 1.181E-05 | 6.431E-03 | BLM, CA9, CASP1, HPGD, HTR2C, NFKB1, POLB |
| BP | GO:0032501; multicellular organismal process | GO:0046541; saliva secretion | 1.236E-05 | 6.563E-03 | CHRM1, CHRM3 |
| BP | GO:0050896; response to stimulus | GO:0007197; adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway | 1.176E-15 | 1.280E-11 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| MF | GO:0060089; molecular transducer activity | GO:0016907; G-protein coupled acetylcholine receptor activity | 1.176E-15 | 1.280E-11 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| BP | GO:0050896; response to stimulus | GO:0007207; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway | 7.050E-15 | 5.117E-11 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| CC | GO:0044456; synapse part | GO:0043679; axon terminus | 3.237E-05 | 1.533E-02 | CHRM1, CHRM2, CHRM3 |
| CC | GO:0045202; synapse | GO:0032279; asymmetric synapse | 3.453E-05 | 1.578E-02 | CHRM2, CHRM3 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 5.316E-05 | 2.158E-02 | CA2, CA9, CHRM3, HPGD |
| MF | GO:0003824; catalytic activity | GO:0097200; cysteine-type endopeptidase activity involved in execution phase of apoptosis | 9.586E-05 | 3.261E-02 | CASP1, CASP7 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.294E-08 | 5.758E-07 | CHRM2, CHRM3, CHRM1, CHRM4, CHRM5, HTR2C, ADRA1D |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 3.236E-08 | 9.601E-07 | CHRM2, CHRM3, CHRM1, CHRM5, HTR2C, ADRA1D |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 1.175E-07 | 2.613E-06 | CHRM2, CHRM3, CHRM1, CHRM4, CHRM5 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.588E-09 | 2.303E-07 | CA12, CA2, CA7, CA9 |
| 09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 3.039E-06 | 5.409E-05 | CHRM2, CHRM3, CHRM1, CHRM4, CHRM5 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 2.920E-05 | 4.332E-04 | CASP7, CASP1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 7.410E-05 | 9.421E-04 | CASP7, CASP1, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 4.690E-04 | 5.217E-03 | CASP7, LMNA, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.300E-03 | 1.285E-02 | CHRM2, CHRM1, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 1.777E-03 | 1.582E-02 | CASP1, NFKB1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| NA: NA | Uveitis | NA | CHRM4; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | CHRM4; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | CHRM2; CHRM4; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | CHRM4; |
| NA: NA | Gastritis | NA | CHRM4; |
| NA: NA | Excessive sweating | NA | CHRM1; |
| NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CHRM1; CHRM3; CHRM4; |
| NA: NA | Dysuria | NA | CHRM4; |
| G00-G99: Diseases of the nervous system G00-G99 | Brain diseases | G00-G99 | CHRM5; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | CHRM4; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CHRM2; |
| J00-J99: Diseases of the respiratory system | Bronchodilator | J45 | CHRM4; |
| H00-H59: Diseases of the eye and adnexa | Acquired nystagmus | H55 | CHRM4; |
| NA: NA | Abdominal stomach pain | NA | CHRM1; |
| NA: NA | Addiction | NA | CHRM2; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM1; CHRM3; CHRM4; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | CHRM5; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | CHRM5; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1; |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | CHRM4; |
| NA: NA | Functional bowel syndrome | NA | CHRM1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | CHRM4; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Amnesia | F04 | CHRM5; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | CHRM5; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | CHRM1; CHRM2; CHRM3; CHRM4; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Postoperative nausea and vomiting | R11 | CHRM3; |
| NA: NA | Vomiting | NA | CHRM4; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CHRM4; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Stabilize muscle contractions | M00-M99 | CHRM2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRM1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA9; |
| NA: NA | Spasms | NA | CHRM3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | CHRM4; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CHRM4; CA9; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnosing bronchial hyperreactivity | W88 | CHRM3; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | CHRM2; |
| NA: NA | Moderate and severe psychomotor agitation | NA | CHRM4; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Sjogren's syndrome | M35.0 | CHRM3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Seborrhea | L21 | CHRM3; |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
| NA: NA | Schizoaffective disorders | NA | CHRM1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | CHRM1; |
| N00-N99: Diseases of the genitourinary system | Overactive bladder | N32.81 | CHRM3; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | CHRM1; CHRM3; CHRM4; CHRM5; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | CHRM3; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | CHRM1; CHRM2; CHRM4; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nocturia | R35 | CHRM4; |
| NA: NA | Dystonia | NA | CHRM1; |
| NA: NA | Peptic ulcer disease | NA | CHRM4; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | CHRM4; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | CHRM1; CHRM2; CHRM4; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | CHRM1; CHRM5; |
| K00-K95: Diseases of the digestive system | Colitis | K50-K52 | CHRM5; |
| NA: NA | Urgency | NA | CHRM4; |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM1; CHRM5; |
| NA: NA | Suprapubic pain | NA | CHRM4; |
| J00-J99: Diseases of the respiratory system | Obstructive lung diseases | J40-J44, J47 | CHRM3; |
| G00-G99: Diseases of the nervous system G00-G99 | Central and peripheral nervous diseases | G96.9 | CHRM4; CHRM5; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CHRM3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Organophosphate poisoning | T60.0 | CHRM4; |
| H00-H59: Diseases of the eye and adnexa | Produce mydriasis and cycloplegia for diagnostic purposes | H57.04 | CHRM4; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRM1; CHRM5; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CHRM1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | CHRM1; CHRM5; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM1; CHRM4; CHRM5; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | CHRM2; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | CHRM1; CHRM2; CHRM3; CHRM5; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Urinary retention | R33 | CHRM4; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | CHRM4; |
| H00-H59: Diseases of the eye and adnexa | Mydriasis diagnosis | H57.0 | CHRM4; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
